期刊文献+

人食管鳞状细胞癌裸小鼠移植瘤模型建立及其应用研究 被引量:5

Establishment and Application of Transplantable Model of Human Esophageal Squamous Cell Carcinoma in Nude Mice
暂未订购
导出
摘要 将人食管癌手术标本直接移植于裸小鼠,建立了人食管鳞状细胞癌裸小鼠移植瘤(Eca910709),其光镜和电镜形态与原发瘤相似。移植瘤中检测到人Alu序列,证明其来源于人体。应用Eca910709,用平阳霉素(BLMA5)对其进行治疗,按15mg/kg腹腔注射给药,经重复实验,抑瘤率为58%-70%(P<0.01),说明BLMA5对Eca910709有明显的抑瘤作用。经三个疗程治疗,Eca910709即对BLMA5产生耐药,表现在抑瘤从70%(P<0.01)递减为34%(P<0.05)和6%(P>0.05)。给药剂量增加至30mg/kg,BLMA5对已耐药的Eca910709再次显示一定的抑瘤作用(抑瘤率为44%,P<0.01)。 A model of the transplantation of human esophageal carcinoma in nude mice (Eca910709) was established by the direct transplantation of a surgical specimen from a patient with esophageal squamous cell carcinoma subcutaneously in the NIH nude mice. Light and electron microscopy showed that the morphology was similar to that of the original tumor. Alu sequence was present in the transplanted tumor, indicating that transplanted tumor was of human origin. Bleomycin was A, used for the treatment of Eca910709. Experimental results showed that Bleomycln A5 exhibited a remarkable growth inhibition on the Eca910709. The inhibition rates of separate experiments were 58% and 70% (P<0. 01 ). The Eca910709 exhibited resistance to Bleomycin A, afrer three courses of treatments. The inhibition rates were significantly decreased from 70% (P<0. 01) to 34%(P<0. 05) then to 6 % (P<0. 05). Increasing the dose of Bleomycin A5·It has exhibited that Bleomycin A, can inhibit tumor in resistant the Eca910709 to a certain drgree. The inhibition rate was 44% (P<0. 01).
出处 《肿瘤防治研究》 CAS CSCD 北大核心 1997年第1期19-21,共3页 Cancer Research on Prevention and Treatment
关键词 食管 鳞状细胞癌 移植瘤模型 平阳霉素 抗药性 Esophageal squamous cell carcinoma Transplanted tumor model Bleomycin A_5 Drug resistance Nudemice
  • 相关文献

同被引文献51

  • 1蔡海英,魏龙星.人食管癌裸鼠移植瘤株建立及其应用的研究[J].中华肿瘤杂志,1993,15(4):248-251. 被引量:2
  • 2邹小农.食管癌流行病学[J].中华肿瘤防治杂志,2006,13(18). 被引量:63
  • 3周剑锋,陈燕,李崇渔,向建平,喻东姣,邹萍,王辨明.阿糖胞苷诱导HL-60细胞凋亡的研究[J].中华肿瘤杂志,1997,19(2):107-110. 被引量:30
  • 4童彤,孙含笑,刘丽影,梁金凤,郭素萍,韩乃君,程书钧.应用末端脱氧核苷酰转移酶法研究化疗药诱导人肿瘤细胞的凋亡[J].中华肿瘤杂志,1997,19(2):111-114. 被引量:6
  • 5Kamangar F, Dores GM, and Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world [J]..J Clin Oncol, 2006, 24: 2137-2150.
  • 6Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002 [J]. CA Cancer J Clin, 2005, 55:74-108.
  • 7Kimura H, Konishi K, Arakawa H, et al. Number of lymph node metastases influences survival in patients with thoracic esoph- ageal carcinoma: therapeutic value of radiation treatment for recurrence [J]. Dis Esophagus, 1999, 12:205-208.
  • 8Mariette C, Balon JM, Piessen G, et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease [J]. Cancer, 2003, 97: 1919-1923.
  • 9Hollingshead MG. Antitumor efficacy testing in rodents [J]. J Natl Cancer Inst, 2008, 100(21):1500-1510.
  • 10Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials [J]. Br J Cancer, 2001, 84(10): 1424-1431.

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部